Lotus Pharmaceutical Placement - Sound Fundamentals but Doesn’t Seem Well Flagged
Lotus Pharmaceutical (1795 TT)'s majority shareholder, Alvogen Emerging Markets Holdings (AEMH), aims to raise up to US$247m through an affiliated...
564 Views
Long Position with Upcoming Catalysts
We expect the complete response letter (CRL) for Andexanet Alfa to be resolved in 2017 and the drug to be launched successfully in the U.S. market....
522 Views